Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.

Osinusi A, Chary A, Winters MA, Naggie S, Masur H, Polis MA, Kottilil S, Holodniy M.

J Med Virol. 2012 Oct;84(10):1522-7. doi: 10.1002/jmv.23376.

2.

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.

Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM.

AIDS. 2011 May 15;25(8):1025-33. doi: 10.1097/QAD.0b013e3283471cae.

3.

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.

Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.

J Viral Hepat. 2014 Mar;21(3):178-88. doi: 10.1111/jvh.12128. Epub 2013 Jul 17.

PMID:
24438679
4.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

5.

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S.

Hepatology. 2012 Aug;56(2):444-54. doi: 10.1002/hep.25647. Epub 2012 Jul 2.

6.

Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.

Toyoda H, Kumada T, Tada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F.

J Med Virol. 2012 Jan;84(1):61-70. doi: 10.1002/jmv.22272.

PMID:
22095536
7.

Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.

Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20.

8.

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.

Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, Lötsch J, Berg T.

J Hepatol. 2011 Mar;54(3):415-21. doi: 10.1016/j.jhep.2010.07.041. Epub 2010 Sep 22.

PMID:
21112657
9.

[Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].

Xu H, Guo LL, He LL, Chen Y, Liu K, Lei BJ, Lei XZ.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2012 Nov;43(6):855-9. Chinese.

PMID:
23387213
10.

Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.

Rallón NI, Soriano V, Naggie S, Restrepo C, McHutchison J, Vispo E, Benito JM.

J Antimicrob Chemother. 2012 May;67(5):1246-9. doi: 10.1093/jac/dkr598. Epub 2012 Feb 1.

11.

Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.

Jia Z, Ding Y, Tian S, Niu J, Jiang J.

PLoS One. 2012;7(9):e45698. doi: 10.1371/journal.pone.0045698. Epub 2012 Sep 21.

12.

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.

Lange CM, Moradpour D, Doehring A, Lehr HA, Müllhaupt B, Bibert S, Bochud PY, Antonino AT, Pascual M, Farnik H, Shi Y, Bechstein WO, Moench C, Hansmann ML, Sarrazin C, Lötsch J, Zeuzem S, Hofmann WP.

J Hepatol. 2011 Aug;55(2):322-7. doi: 10.1016/j.jhep.2010.10.037. Epub 2010 Dec 13.

PMID:
21147186
13.

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, Palomares JC, Mira JA, Martínez A, Roldán C, de la Torre J, Macías J.

Clin Infect Dis. 2010 Oct 1;51(7):788-95. doi: 10.1086/656235.

PMID:
20804372
14.

A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.

Yuan H, Adams-Huet B, Petersen T, Attar N, Lee WM, Jain MK.

J Med Virol. 2012 Dec;84(12):1913-9. doi: 10.1002/jmv.23407.

15.

Low IL10 serum levels as key factor for predicting the sustained virological response to IFNα/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype.

Vasconcelos LR, Moura P, do Carmo RF, Pereira LB, Cavalcanti Mdo S, Aroucha DC, Dutra RA, Pereira LM.

Hum Immunol. 2014 Aug;75(8):895-900. doi: 10.1016/j.humimm.2014.06.017. Epub 2014 Jun 30.

PMID:
24994464
16.

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.

Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S.

World J Gastroenterol. 2016 Mar 28;22(12):3418-31. doi: 10.3748/wjg.v22.i12.3418.

17.

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.

Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B.

J Hepatol. 2013 Jul;59(1):18-23. doi: 10.1016/j.jhep.2013.02.009. Epub 2013 Feb 22.

PMID:
23439262
18.

HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.

Stenkvist J, Sönnerborg A, Weiland O.

J Viral Hepat. 2013 Mar;20(3):193-9. doi: 10.1111/j.1365-2893.2012.01645.x. Epub 2012 Aug 21.

PMID:
23383658
19.

Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.

Di Lello FA, Caruz A, Rallon NI, Rivero-Juarez A, Neukam K, Barreiro P, Camacho A, García-Rey S, Rivero A, Soriano V, Cifuentes C, Macias J, Pineda JA.

Eur J Clin Microbiol Infect Dis. 2013 Nov;32(11):1427-35. doi: 10.1007/s10096-013-1894-9. Epub 2013 May 29.

PMID:
23715768
20.

Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.

Chary A, Winters MA, Kottilil S, Murphy AA, Polis MA, Holodniy M.

J Infect Dis. 2010 Sep 15;202(6):889-93. doi: 10.1086/655784.

Supplemental Content

Support Center